LigaChem Biosciences Inc. (141080.KQ)

65,500.00 -700.00 (-1.06%) At close: 03:30PM KST

LigaChem Biosciences Inc.

10, Gukjegwahak 10-ro
Yuseong-gu
Daejeon 34002
South Korea
82 4 2861 0688
https://www.legochembio.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Yong Zu Kim	CEO & President	N/A	N/A	1956
Mr. Sejin Park	CFO, COO & Vice President	N/A	N/A	1962
Mr. Yeong Soo Oh	Chief Technology Officer and Executive Vice President	N/A	N/A	1959
Mr. Jeiwook Chae	Chief Business Development Officer	N/A	N/A	N/A
Dr. Young-Lag Cho Ph.D.	Chief Development Officer & Head Researcher & Development	N/A	N/A	N/A
Dr. Chul-Woong Chung	Head of ADC Center	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

LigaChem Biosciences Inc. a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, and oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It offers its products in the forms of tablets and capsules. The Company also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. LigaChem Biosciences Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.

Corporate governance

LigaChem Biosciences Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.